Core Insights - Merck reported positive results from late-stage studies on a new oral treatment combining doravirine and islatravir for adults with HIV-1 [2] - The studies focused on adults whose HIV was under control using another treatment called bictegravir/emtricitabine/tenofovir alafenamide [2]